Despite the prominent success of TKI in controlling the CML chronic phase, a high number of CML patients still develop drug resistance or relapsed after molecular response; these could be attributed to the failure of TKIs to eradicate all CD34+CD38- SCs, which are responsible for CML relapse (Zhou and Xu, 2015). Here, CD38 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.